Synonym
Deacetylanisomycin; (-)-Deacetylanisomycin; Anisomycin, deacetyl-; SA 3097D1; SA3097D1; SA-3097D1
IUPAC/Chemical Name
(2R,3S,4S)-2-((4-Methoxyphenyl)methyl)-3,4-pyrrolidinediol
InChi Key
UMWAPBCLJQSOJX-WOPDTQHZSA-N
InChi Code
InChI=1S/C12H17NO3/c1-16-9-4-2-8(3-5-9)6-10-12(15)11(14)7-13-10/h2-5,10-15H,6-7H2,1H3/t10-,11+,12+/m1/s1
SMILES Code
O[C@H]1[C@@H](CC2=CC=C(OC)C=C2)NC[C@@H]1O
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
223.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kim JH, Curtis-Long MJ, Seo WD, Ryu YB, Yang MS, Park KH. Stereodivergent syntheses of anisomycin derivatives from D-tyrosine. J Org Chem. 2005 May 13;70(10):4082-7. PubMed PMID: 15876100.
2: Ramirez RR, Gandhi CC, Muzzio IA, Matzel LD. Protein synthesis-dependent memory and neuronal enhancement in Hermissenda are contingent on parameters of training and retention. Learn Mem. 1998 Mar-Apr;4(6):462-77. PubMed PMID: 10701872.
3: Kanbe K, Mimura Y, Tamamura T, Yatagai S, Sato Y, Takahashi A, Sato K, Naganawa H, Nakamura H, Takeuchi T, et al. AB3217-A, a novel anti-mite substance produced by a strain of Streptomyces platensis. J Antibiot (Tokyo). 1992 Apr;45(4):458-64. Erratum in: J Antibiot (Tokyo) 1992 Jun;45(6):C-2. PubMed PMID: 1592678.
4: Ekong RM, Kirby GC, Patel G, Phillipson JD, Warhurst DC. Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesis. Biochem Pharmacol. 1990 Jul 15;40(2):297-301. PubMed PMID: 2198027.
5: Crow T, Forrester J. Inhibition of protein synthesis blocks long-term enhancement of generator potentials produced by one-trial in vivo conditioning in Hermissenda. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4490-4. PubMed PMID: 2352932; PubMed Central PMCID: PMC54141.
6: Alkon DL, Bank B, Naito S, Chen C, Ram J. Inhibition of protein synthesis prolongs Ca2+-mediated reduction of K+ currents in molluscan neurons. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6948-52. PubMed PMID: 3477819; PubMed Central PMCID: PMC299202.
7: Eskin A, Yeung SJ, Klass MR. Requirement for protein synthesis in the regulation of a circadian rhythm by serotonin. Proc Natl Acad Sci U S A. 1984 Dec;81(23):7637-41. PubMed PMID: 6095312; PubMed Central PMCID: PMC392203.
